Jul. 8 at 12:35 PM
$NKGN From Dr. Song’s Facebook, “Enjoying a glorious day in Tokyo with Rob Claar and the Heka Bio team who are working with NKGen Biotech to bring our NK cell therapy (troculeucel) to the Japanese market. Under Japan’s Yokohama declaration for regenerative medicine, we will soon begin commercial sales and treatment pending official inspections of our Korea and U.S. GMP facilities by the Japanese regulatory authorities. Our goal is to launch later this year.”